CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 21 enrolled
Drug / intervention
VEGF-TKI +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02944617
NCT02944617N/ACompleted

Assessment of the Role of Bifidobacterium-Containing Food Supplement Activia™ and Bacteriomic Profiling and Other Biomarkers Associated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor (VEGF-TKI)-Induced Diarrhea in Patients With Metastatic Renal Cell Carcinoma (mRCC)

City of Hope Medical Center·interventional·Posted Oct 26, 2016·Updated Feb 23, 2024

In Brief

A clinical study evaluating Laboratory Biomarker Analysis, Micronutrient-Fortified Probiotic Yogurt, and 1 other intervention for Diarrhea and 2 related conditions. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This randomized clinical trial studies how well probiotic yogurt supplement works in reducing diarrhea in patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) and that are being treated with vascular endothelial growth factor-tyrosine kinase inhibitor therapy. Studying samples of blood and stool from patients who eat probiotic yogurt and those who avoid probiotic yogurt may help doctors plan better treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 26, 2016
Enrollment StartNov 11, 2016
Primary CompletionDec 19, 2021
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 9.7 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Micronutrient-Fortified Probiotic Yogurtdietary

Receive Activia yogurt

VEGF-TKIdrug

Must be received as standard of care chemotherapy